Cue Biopharma Announces Strategic Prioritization Of Autoimmune Programs; Anticipates Annualized Capital And Workforce Requirements To Be Reduced By ~25%; Expects To Reduce Its FY25 Operating Expenses By ~25%, To A Projected Annual Cash Burn, Based...
Cue Biopharma Announces Strategic Prioritization Of Autoimmune Programs; Anticipates Annualized Capital And Workforce Requirements To Be Reduced By ~25%; Expects To Reduce Its FY25 Operating Expenses By ~25%, To A Projected Annual Cash Burn, Based...
Cue Biopharma Announces Strategic Prioritization Of Autoimmune Programs; Anticipates Annualized Capital And Workforce Requirements To Be Reduced By ~25%; Expects To Reduce Its FY25 Operating Expenses By ~25%, To A Projected Annual Cash Burn, Based Upon Current Assumptions, Of ~$30M
Cue biopharma宣布重点优化自身的自身免疫项目，预计资本和工作力年平均需求将减少约25％；预计到2025财年营业费用将减少约25％，按照当前的假设，将会有约3000万美元的预计年现金流失。
Prioritizing autoimmune programs aims to focus upon near-term and intermediate value creation potential, while retaining oncology programs as promising clinical data continues to mature
优先考虑自身的自体免疫计划，旨在使有前途的临床数据的肿瘤计划继续成熟。
- Company anticipates annualized capital and workforce requirements to be reduced by approximately 25 percent
- 公司预计资本和工作力年平均需求将减少约25％
BOSTON, July 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced the strategic prioritization of its autoimmune programs and organizational restructuring to strengthen operational efficiencies while enabling its encouraging oncology survival data to continue to mature.
2024年7月25日，美国波士顿（GLOBE NEWSWIRE） - 生物制品公司Cue biopharma（NASDAQ：CUE）公布了其自身免疫项目的战略重点，并进行了组织重组以加强运营效率，同时使其令人鼓舞的肿瘤生存数据能够继续成熟。该公司开发了一种新型治疗生物制品，能够选择性地参与和调节特定于疾病的T细胞。